Glutamatergic neurons are the primary excitatory cells in the mammalian central nervous system, utilizing the neurotransmitter glutamate to communicate across synapses. These neurons are widely distributed throughout the brain, with high concentrations in regions such as the cerebral cortex, hippocampus, and cerebellar cortex. Their activity underpins essential processes like learning, memory, and cognition, making them fundamental to healthy brain function. Glutamatergic neurons achieve excitatory synaptic transmission by releasing glutamate from synaptic vesicles into the synaptic cleft, a process tightly regulated by proteins such as vesicular glutamate transporter 1 (VGLUT1). Disruptions in glutamatergic signaling are linked to a range of neurological disorders, including amyotrophic lateral sclerosis, Alzheimer’s disease, and other neurodegenerative conditions. As the most abundant neuron type in the nervous system, understanding the biology and function of glutamatergic neurons is crucial for unraveling the complexities of brain health and disease.

Neurological disorders

Glutamatergic neurons play a pivotal role in the pathophysiology of many neurological disorders. Dysregulation of glutamatergic neurotransmission has been implicated in a variety of neurodegenerative diseases, including Alzheimer’s disease, amyotrophic lateral sclerosis, and Huntington’s disease. These conditions often involve alterations in glutamate signaling, leading to excitotoxicity and neuronal damage. Beyond neurodegeneration, glutamatergic neurons are also central to the development of neurodevelopmental disorders such as autism spectrum disorder and schizophrenia, where imbalances in excitatory and inhibitory signaling can disrupt normal brain function. Advances in genetic and molecular tools, including the use of animal models and viral vector systems, are helping researchers unravel the complex roles of glutamatergic neurons in these diseases. By targeting specific genes or proteins involved in glutamatergic neurotransmission, scientists are paving the way for novel therapeutic approaches aimed at restoring healthy neuronal function and mitigating the impact of neurological disorders.

Future directions

Glutamatergic neurons are indispensable to the proper functioning of the mammalian central nervous system, orchestrating excitatory synaptic transmission and supporting cognitive and behavioral processes. Their involvement in a wide spectrum of neurological disorders underscores the importance of continued research into glutamatergic neurotransmission. Emerging technologies, such as viral vector systems and advanced microscopy techniques, are expanding our ability to study these neurons in unprecedented detail. Future research should focus on elucidating the molecular mechanisms that govern glutamatergic signaling and its dysregulation in disease states. The development of innovative therapeutic strategies, including gene therapy and targeted small molecule treatments, holds promise for addressing the unmet needs of patients with neurological disorders. As our understanding of glutamatergic neurons deepens, so too does the potential for breakthroughs in the diagnosis, treatment, and prevention of many devastating conditions affecting the nervous system.

Vesicular glutamate transporter 1

Vesicular glutamate transporter 1 (vGluT1) is a protein predominantly expressed in glutamatergic neurons, particularly within neuron-rich regions of the brain such as the cerebral cortex and hippocampus. It is localized to the membranes of synaptic vesicles, where it plays a critical role in loading glutamate, the primary excitatory neurotransmitter in the central nervous system, into vesicles for synaptic release. Due to its specific expression pattern and functional role, vGluT1 serves as a highly reliable molecular marker for identifying glutamatergic synapses. Its presence is widely used in neuroanatomical and functional studies to map excitatory circuits in the brain.

Figure 1. Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VGluT1 antibody [EPR22269] (ab227805).

Recommended products

Vesicular glutamate transporter 2

Vesicular glutamate transporter 2 (vGluT2) is a key protein involved in excitatory neurotransmission, responsible for transporting cytoplasmic glutamate into synaptic vesicles for release at glutamatergic synapses. Unlike vGluT1, which is more prominent in cortical regions, vGluT2 is typically expressed in subcortical and brainstem areas, including the thalamus and midbrain. Its expression pattern reflects regional differences in glutamatergic neuron populations and is frequently analyzed to study the anatomical and functional organization of excitatory circuits. As such, vGluT2 serves as a robust molecular marker for identifying and mapping glutamatergic neurons in specific brain regions.

Figure 2. Immunohistochemistry (Frozen sections) - Anti-VGLUT2 antibody [EPR21085] (ab216463).

Recommended products

Glutamate Ionotropic Receptor NMDA Type Subunit 1

N-Methyl-D-Aspartate Receptor Subunit 1 (NMDAR1 or GluN1) is an essential and ubiquitously expressed component of all functional NMDA receptors, a subtype of ionotropic glutamate receptors. This subunit is required for receptor assembly and surface expression, making it a fundamental marker for glutamatergic signaling. NMDA receptors are critical mediators of synaptic plasticity, learning, and memory, as they enable calcium influx in response to glutamate binding and postsynaptic depolarization. While glutamate binds primarily to the NR2 (GluN2) subunits, the presence of NMDAR1 is indispensable for receptor activation. Its widespread expression across the brain makes it a reliable molecular indicator of glutamatergic synapses and excitatory neurotransmission.

Figure 3. Western blot - Anti-NMDAR1 antibody [EPR2481(2)] - Neuronal Marker (ab109182).

Recommended products

Glutamate Ionotropic Receptor NMDA Type Subunit 2B

N-Methyl-D-Aspartate Receptor Subunit 2B (NMDAR2B or GluN2B) is a critical component of NMDA receptors, which are ionotropic glutamate receptors involved in excitatory neurotransmission and synaptic plasticity. Although all NMDA receptors require the NMDAR1 subunit for functional assembly, the NMDAR2B subunit contributes to receptor diversity and modulates channel properties such as kinetics and calcium permeability. Its expression overlaps with other NMDA receptor subunits across many brain regions, but it is particularly enriched during early development and in specific areas like the forebrain. NMDAR2B is widely used as a molecular marker to study glutamatergic neuron distribution and receptor composition in both developmental and functional contexts.

Figure 4. Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NMDAR2B antibody [EPR23460-119] (ab254356).

Recommended products

Glutaminase

Glutaminase is a mitochondrial enzyme that plays a central role in the glutamate–glutamine cycle, a key metabolic pathway in excitatory neurotransmission. It catalyzes the conversion of glutamine into glutamate, the principal excitatory neurotransmitter in the central nervous system. This enzymatic activity is essential for maintaining adequate levels of glutamate within presynaptic terminals, particularly in glutamatergic neurons. Glutaminase is often considered a neuron-specific marker in many studies, as its expression is enriched in neuronal populations involved in excitatory signaling. Its presence is widely used to identify and characterize glutamatergic neurons in both developmental and functional neuroanatomical analyses.

Figure 5. Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Glutaminase antibody [EP7212] (ab156876).

Recommended products

Glutamine synthetase

Glutamine synthetase (GS) is a key enzyme in the glutamate–glutamine cycle, catalyzing the ATP-dependent conversion of glutamate into glutamine. It is primarily expressed in astrocytes, where it plays a crucial role in maintaining neurotransmitter balance by detoxifying excess glutamate and supplying neurons with glutamine for glutamate resynthesis. Although traditionally considered a glial marker, GS expression can increase in neurons under certain conditions, such as during neurodegenerative diseases or postnatal development, reflecting shifts in cellular identity and maturation. Transcriptional regulation by specific factors further influences GS expression across neural cell types, making it a dynamic marker for studying glutamatergic metabolism and neuron-glia interactions.

Figure 6. Immunohistochemistry (Frozen sections) - Anti-Glutamine Synthetase antibody [EPR13022(B)] (ab176562).

Recommended products

References

1. Baude, A., Strube, C., Tell, F.  et al.  Glutamatergic neurotransmission in the nucleus tractus solitarii: structural and functional characteristics.  J. Chem. Neuroanat.  383, 145–153 (2008).

2. Wang, T., Miller, K.E. Characterization of glutamatergic neurons in the rat atrial intrinsic cardiac ganglia that project to the cardiac ventricular wall.  Neuroscience  329, 134–150 (2016).

3. Bhatt, J.M., Prakash, A., Suryavanshi, P.S.  et al.  Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating.  Mol. Pharmacol.  83, 9–21 (2013).

4. Fischer, G., Mutel, V., Trube, G.  et al.  Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit.  J. Pharmacol. Exp. Ther.  283, 1285–1292 (1997).

5. Kovacic, P., Somanathan, R. Clinical physiology and mechanism of dizocilpine (MK-801): electron transfer, radicals, redox metabolites and bioactivity.  Oxid. Med. Cell. Longev.  3, 13–22 (2010).

6. Liu, S.B., Ma, L., Guo, H.J.  et al.  Gentiopicroside attenuates morphine rewarding effect through downregulation of GluN2B receptors in nucleus accumbens.  CNS Neurosci. Ther.  18, 652–658 (2012).

7. North, W.G., Gao, G., Jensen, A.  et al.  NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment.  Clin. Pharmacol.  2, 31–40 (2010).

8. Prybylowski, K., Chang, K., Sans, N.  et al.  The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2.  Neuron  47, 845–857 (2005).

9. Fernandes, S.P., Dringen, R., Lawen, A.  et al.  Neurones express glutamine synthetase when deprived of glutamine or interaction with astrocytes.  J. Neurochem.  114, 1527–1536 (2010).